12th week of 2009 patent applcation highlights part 51 |
Patent application number | Title | Published |
20090075916 | Use of Macrolide Derivatives for Treating Acne - This invention relates to 14-membered macrolide derivatives for treating or preventing acne vulgaris and associated inflammatory conditions. Also provided herein are medicaments or pharmaceutical compositions comprising one or more 14-membered macrolide derivatives together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof, and methods for treating or preventing acne vulgaris and associated inflammatory conditions. | 2009-03-19 |
20090075917 | DEUTERIUM-ENRICHED TELITHROMYCIN - The present application describes deuterium-enriched telithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075918 | VETERINARIAN COMPOSITION COMPRISING AN ORGANIC SALT OF LEVAMISOLE IN COMBINATION WITH AT LEAST ONE AVERMECTINE AND/OR MILBEMYCINE - Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine. A veterinarian formulation comprising of organics salts of levamisole, more specifically to the disophenolat salt of levamisole and the nitroxynil-salt of levamisole with avermectines and milbemycines and its use in treatment of helminthiasis in mammals, in particular in bovines, swines, caprines, equines, ovines, canines and felines. | 2009-03-19 |
20090075919 | Anti-neoplastic compositions comprising extracts of black cohosh - The present invention provides a composition for use in treating or preventing neoplasia, comprising an effective actein. The present invention also provides a composition for use in treating or preventing neoplasia, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh. The present invention further provides a combination of anti-neoplastic agents, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh and an effective anti-neoplastic amount of at least one additional chemopreventive or chemotherapeutic agent. Methods for treating and preventing neoplasia are also provided. | 2009-03-19 |
20090075920 | DEUTERIUM-ENRICHED DECITABINE - The present application describes deuterium-enriched decitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075921 | Bone/joint disease sensitivity gene and use thereof - The present invention provides the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of calmodulin, the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of asporin, and a diagnostic method for genetic susceptibility to bone and joint diseases by detecting polymorphisms in the CALM1 gene and/or the asporin gene, and the like. | 2009-03-19 |
20090075922 | Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met - The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors. | 2009-03-19 |
20090075923 | Methods of treatment of renal disease - The invention is directed to a process of identifying a compound capable of inhibiting the activity of a human Ax1 receptor that comprises contacting the Ax1 receptor or cells expressing the Ax1 receptor with the compound; measuring the Ax1 receptor activity in the presence of the compound; and comparing the activity measured to that measured in the absence of the compound under controlled conditions, wherein a decrease identifies the compound as being capable of inhibiting the activity. Therapeutic and diagnostic applications are also described. | 2009-03-19 |
20090075924 | MODULATION OF APOLIPOPROTEIN (a) EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided. | 2009-03-19 |
20090075925 | Methods and Compositions Related to APOBEC-1 Expression - Disclosed are methods and compositions related to ACF and to APOBEC-1. | 2009-03-19 |
20090075926 | METHOD FOR IDENTIFYING AND MANIPULATING CELLS - The present application discloses a method of isolating or selecting stem cells from a mixed population containing stem cells, which includes the population of cells with a ligand specific for a truncated MUC1 receptor, wherein the presence of the truncated MUC1 receptor on the cells indicates that they are stem cells. | 2009-03-19 |
20090075927 | SWEET TASTE RECEPTORS - This invention provides novel genes and polypeptides of the sweet receptor family, methods for production of the polypeptides, methods for screening compounds that specifically bind to and/or modulate the activity of these polypeptides; and antibodies specific for the polypeptides. | 2009-03-19 |
20090075928 | G-QUARTET OLIGONUCLEOTIDES THAT TARGET HYPOXIA-INDUCIBLE FACTOR 1-a (HIF1a ) - The present invention concerns particular G-quartet oligonucleotides that are employed for the treatment and/or prevention of cancer. In specific cases, the G-quartet oligonucleotides inhibit HIF-1α. | 2009-03-19 |
20090075929 | IG20 SPLICE VARIANTS THERAPEUTICS FOR CANCER - Methods and compositions inhibit the growth of cancer cells by selectively down-regulating the expression of an IG20 splice variant including MADD. Specific knock-down of MADD splice variant resulted in the apoptosis of cancer cells. Interfering RNAs including small hairpin RNAs (shRNA) to down-regulate MADD expression in vivo are disclosed. Inhibition of MADD phosphorylation by Akt results in activation of cancer cell death. Down-regulation of MADD expression results in switching to apoptotic mode due to lack of MAPK activation upon TNF-α-based induction. | 2009-03-19 |
20090075930 | DEUTERIUM-ENRICHED NELARABINE - The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075931 | DEUTERIUM-ENRICHED CAPECITABINE - The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075932 | METHOD OF SELECTIVELY INHIBITING PKCiota - PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1α,2β,3β,4α)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota. | 2009-03-19 |
20090075933 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 2009-03-19 |
20090075934 | USE OF SULFATED OLIGOSACCHARIDES AS SLIMMING COSMETIC INGREDIENTS - This invention relates to the use of a preparation comprising sulfated oligosaccharides which trap spermine or spermidine or both, as an active slimming ingredient in a cosmetic, pharmaceutical and/or nutraceutical composition. | 2009-03-19 |
20090075935 | COMPOSITION COMPRISING AT LEAST ONE C-GLYCOSIDE DERIVATIVE AND AT LEAST ONE HYALURONIC ACID AND ITS COSMETIC USE - The present invention relates to a topical cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one hyaluronic acid or a derivative thereof and at least one C-glycoside derivative. | 2009-03-19 |
20090075936 | Proteasome inhibitors and methods of using the same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity. | 2009-03-19 |
20090075938 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (1): A | 2009-03-19 |
20090075939 | Novel HIV reverse transcriptase inhibitors - The invention is related to compounds of Formula (I): | 2009-03-19 |
20090075940 | DEUTERIUM-ENRICHED RISEDRONATE - The present application describes deuterium-enriched risedronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075941 | TREATING NEOPLASMS - Methods of treating a subject with neoplasm (e.g., mesothelioma) or at risk of developing neoplasm by administering a mevalonate pathway inhibitor such as a nitrogen-containing bisphosphonate are disclosed. Examples of nitrogen-containing bisphosphonates include alendronate, ibandronate, minodronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronate. The methods can further include the administration of a p38 inhibitor. Further disclosed are compositions and kits including a nitrogen-containing bisphosphonate and optionally a p38 inhibitor. | 2009-03-19 |
20090075942 | DEUTERIUM-ENRICHED FOSAMPRENAVIR - The present application describes deuterium-enriched fosamprenavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075943 | Combretastatin Analogs with Tubulin Binding Activity - Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature. | 2009-03-19 |
20090075944 | DEUTERIUM-ENRICHED IBANDRONATE - The present application describes deuterium-enriched ibandronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075945 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents - Novel phosphate-bearing prodrugs of sulfonyl hydrazines have the formula presented below. Methods of treatment of cancer are claimed. The aforementioned prodrugs include enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates and metabolites from all stages. The aforementioned prodrugs are preferentially activated in hypoxic tumors and can be given either alone, or in combination with other anticancer agents or with phototheraphy or radiotherapy. | 2009-03-19 |
20090075946 | NOVEL TRITERPENIC ACID DERIVATIVE AND PREPARATION FOR EXTERNAL APPLICATION FOR SKIN COMPRISING THE SAME - In a triterpenic acid having hydroxyl groups, at least one of the hydroxyl groups is phosphorylated to produce a phosphorylated triterpenic acid and/or a salt thereof, thereby improving the solubility of the triterpenic acid in a preparation for external application for the skin and allowing the physiological activity of the triterpenic acid to be exerted satisfactorily. The phosphorylated triterpenic acid is preferably, for example, ursolic acid phosphate and/or a salt thereof. The preparation for external application for the skin is preferably a cosmetic, particularly preferably a quasi-drug. | 2009-03-19 |
20090075947 | DEUTERIUM-ENRICHED FOSPROPOFOL - The present application describes deuterium-enriched fospropofol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075948 | COMPOSITIONS AND METHODS FOR REGULATING CELLULAR PROTECTION - The invention provides a method of inducing a protective response in cells by activating a heat shock response, via heat shock transcription factor (HSF), without stressing the cells. The invention is based on the surprising discovery that HSF can be activated in non-stressed cells by disrupting interaction with the repressive cognate protein, Hsc70. As described herein, non-steroidal anti-inflammatory drugs (NSAID), including salicylic acid and ibuprofen, can stimulate HSF DNA binding, Hsp70 transcription and Hsp70 protein synthesis in non-stressed cells. By activating HSF, the degenerative effects of certain neurodegenerative proteins such as polyglutamine repeat proteins (Huntington's disease) and the α-synuclein protein (Parkinson's disease) can be offset. The invention thus provides a method of ameliorating symptoms of neurodegenerative disease. | 2009-03-19 |
20090075949 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases - The invention relates to a method of treating and preventing thromboembolic disorders, comprising administering dipyridamole in combination with an antithrombotic selected from direct thrombin inhibitors, factor Xa inhibitors and combined thrombin/factor Xa inhibitors to a patient, pharmaceutical compositions suitable for this method of treatment as well as the use of dipyridamole for the manufacture of these pharmaceutical compositions. | 2009-03-19 |
20090075950 | Dosage Forms Containing A PPI, NSAID And A Buffer - Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form. | 2009-03-19 |
20090075951 | Methods and Reagents for the Treatment of Inflammatory Disorders - The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tricyclic compound and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing a tricyclic compound and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder. | 2009-03-19 |
20090075952 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS - Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X | 2009-03-19 |
20090075953 | DEUTERIUM-ENRICHED ED-71 - The present application describes deuterium-enriched ED-71, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075954 | SOFT ANTICHOLINERGIC ESTERS - Soft anticholinergic esters of the formulas: | 2009-03-19 |
20090075955 | Therapeutic regimens for the treatment of immunoinflammatory disorders - The invention features pharmaceutical compositions and dosing regimens for the treatment of immunoinflammatory disorders. | 2009-03-19 |
20090075956 | Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 - The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate. | 2009-03-19 |
20090075957 | XANTHOHUMOL COMPOSITIONS AND METHODS OF USING SAME - The present invention provides compositions comprising an effective amount of xanthohumol and honokiol. The present invention comprises compositions comprising an effective amount of xanthohumol and genistein. The present invention comprises compositions comprising an effective amount of xanthohumol and guggulsterone. The compositions of the present invention may be effective to decrease mature adipocytes viability, induce apoptosis of mature adipocytes, increase lipolysis in mature adipocytes, and/or reduce adipogenesis during the maturation of pre-adipocytes. The present invention further provides methods of treating obesity, diabetes, osteoporosis or bone disorders in a subject, which comprise administering to the subject compositions comprising an effective amount of xanthohumol and honokiol, guggulsterone, or genistein. | 2009-03-19 |
20090075958 | CLOBETASOL PROPIONATE SHAMPOOS FOR THE TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP - Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith. | 2009-03-19 |
20090075959 | DEUTERIUM-ENRICHED CICLESONIDE - The present application describes deuterium-enriched ciclesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075960 | Method of treating gaucher disease - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 2009-03-19 |
20090075961 | Testosterone Oral Dosage Formulations And Associated Methods - Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance. | 2009-03-19 |
20090075962 | GROWTH STIMULANT COMPOSITIONS - An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection. | 2009-03-19 |
20090075963 | TRANSDERMAL HORMONE SPRAY - The present invention provides a transdermal spray drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention. | 2009-03-19 |
20090075964 | FRAGRANCE COMPOSITIONS AND OTHER COMPOSITIONS WHICH CONTAIN NATURALLY OCCURRING SUBSTANCES FOUND IN CORALS - This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to methods of affecting the mood of individuals using such compounds. | 2009-03-19 |
20090075965 | DEUTERIUM-ENRICHED AMOXICILIN - The present application describes deuterium-enriched amoxicilin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075966 | DEUTERIUM-ENRICHED TAZOBACTAM - The present application describes deuterium-enriched tazobactam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075967 | DEUTERIUM-ENRICHED CEFTRIAXONE - The present application describes deuterium-enriched ceftriaxone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075968 | CETP inhibitors - The present invention relates to a compound of formula | 2009-03-19 |
20090075969 | DEUTERIUM-ENRICHED DORIPENEM - The present application describes deuterium-enriched doripenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075970 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor - Thieno- and furo-pyrimidine compounds are described, which are useful as H | 2009-03-19 |
20090075971 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME - The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide derivatives, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds, and to intermediate precursors to such compounds. | 2009-03-19 |
20090075972 | Use of Midostaurin for Treating Gastrointestinal Stromal Tumors - The present invention relates to the use of midostaurin, in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of gastrointestinal stromal tumors, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of midostaurin is administered to an animal suffering from said disease or condition. | 2009-03-19 |
20090075973 | BENZO-FUSED HETEROCYCLES - The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof. | 2009-03-19 |
20090075974 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS - Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity. | 2009-03-19 |
20090075975 | ARYLSULFONAMIDES AND USES RELATED THERETO - Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: | 2009-03-19 |
20090075976 | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor - The present invention relates to the association of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also to pharmaceutical compositions containing them, and to methods of treating vascular complications associated with diabetes, with atherothrombotic diseases, with hyperlipidaemia, with hypertension, with chronic venous diseases, with inflammation, with metabolic syndrome associated with obesity, or with cancer, with such association. | 2009-03-19 |
20090075977 | DEUTERIUM-ENRICHED MK0974 - The present application describes deuterium-enriched MK-0974, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075978 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS - The present invention relates to substituted propiolic acid amides, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments. | 2009-03-19 |
20090075979 | CETP Inhibitors - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R | 2009-03-19 |
20090075980 | Pyrazolopyridines and Analogs Thereof - Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 2009-03-19 |
20090075981 | INHIBITORS OF p38 - The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders. | 2009-03-19 |
20090075982 | Piperazine compounds - A compound selected from those of formula (I): | 2009-03-19 |
20090075983 | Novel Diazabicycloalkane Derivatives and Their Medical Use - This invention relates to novel diaza-bicyclo-alkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2009-03-19 |
20090075984 | Materials and methods relating to protein aggregation in neurodegenerative disease - The present invention is directed to methods for the treatment or prophylaxis of a tauopathy comprising administering to a patient in need thereof a medicament comprising a phenothiazine. | 2009-03-19 |
20090075985 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE - Aryl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula | 2009-03-19 |
20090075986 | Anti-inflammatory medicaments - Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds. | 2009-03-19 |
20090075987 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS - The present invention relates to acyltryptophanols of the general formula I, | 2009-03-19 |
20090075988 | CYANOISOQUINOLINE - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2009-03-19 |
20090075989 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS - The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, | 2009-03-19 |
20090075990 | Aerosol Formulation for Inhalation Containing an Anticholinergic Agent - The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X | 2009-03-19 |
20090075991 | DEUTERIUM-ENRICHED EFAVIRENZ - The present application describes deuterium-enriched efavirenz, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075992 | Pteridine Derivatives as Nitric Oxide Synthase Activators - The present invention relates to the use of pteridine derivatives as nitric oxide synthase activators. In particular, the derivatives find use in the treatment of diseases associated with endothelial dysfunction such as cardiovascular diseases. | 2009-03-19 |
20090075993 | Pharmaceutically effective compounds - The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases. | 2009-03-19 |
20090075994 | DEUTERIUM-ENRICHED RADAFAXINE - The present application describes deuterium-enriched radafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075995 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): | 2009-03-19 |
20090075996 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia. | 2009-03-19 |
20090075997 | DEUTERIUM-ENRICHED SATAVAPTAN - The present application describes deuterium-enriched satavaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090075998 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors - The invention encompasses novel compounds of Formula I | 2009-03-19 |
20090075999 | OXYGEN LINKED PYRIMIDINE DERIVATIVES - The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases. | 2009-03-19 |
20090076000 | DEUTERIUM-ENRICHED MYCOPHENOLATE MOFETIL - The present application describes deuterium-enriched mycophenolate mofetil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076001 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments - The present invention relates to substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compound corresponding to formula I, methods for producing them, to medicaments containing these compounds, the use of these compounds for producing medicaments and related treatment methods | 2009-03-19 |
20090076002 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - The invention relates to amino alcohol-substituted arylthienopyrimidinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one amino alcohol-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the amino alcohol-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists. | 2009-03-19 |
20090076003 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity - The invention relates to new phthalazine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment of a disease, especially of a disease that responds to the inhibition of tyrosine kinases, more especially the inhibition of the vascular endothelial growth factor (VEGF) receptor kinase, preferably the treatment of a proliferative disease, such as a tumour disease. | 2009-03-19 |
20090076004 | Indoles Useful in the Treatment of Inflammation -
There is provided compounds of formula (I), wherein X | 2009-03-19 |
20090076005 | Kinase inhibitor compounds - The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes. | 2009-03-19 |
20090076006 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to HSP90 inhibitors containing a zinc binding moiety and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors. | 2009-03-19 |
20090076007 | DEUTERIUM-ENRICHED APREPITANT - The present application describes deuterium-enriched aprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076008 | DEUTERIUM-ENRICHED FOSAPREPITANT - The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076009 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS - The invention concerns thiazole derivatives of Formula I | 2009-03-19 |
20090076010 | DEUTERIUM-ENRICHED LAMOTRIGINE - The present application describes deuterium-enriched lamotrigine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076011 | DEUTERIUM-ENRICHED TIRAPAZAMINE - The present application describes deuterium-enriched tirapazamine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076012 | Modulation of pathogenicity - The present invention relates to the use of compounds of the general Formula (I): | 2009-03-19 |
20090076013 | DEUTERIUM-ENRICHED SITAGLIPTIN - The present application describes deuterium-enriched sitagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
20090076014 | Methods of Administering Tetrahydrobiopterin, Associated Compositions, And Methods of Measuring - The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample. | 2009-03-19 |
20090076015 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring - It is intended to provide an anticoagulant that has an extremely excellent FXa inhibitory action and an extremely weak hERG channel inhibitory action and can be orally administered, which is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. | 2009-03-19 |
20090076016 | FORMULATIONS COMPRISING JORUMYCIN-, RENIERAMYCIN-, SAFRACIN- OR SAFRAMYCIN-RELATED COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES - Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided. | 2009-03-19 |